N/A N=60 Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men
HIV/AIDS · Substance Use · Bisexuality
Primary: Retention — 25; 26 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=65 Safety and Immunogenicity of a Chlamydia Vaccine CTH522
Trachoma
Primary: Solicited Local Injection Site Reactions — 2; 8; 3; 9 Participants — p=1
N/A N=40 Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator
Tachycardia · Diabetes Mellitus · Cardiovascular Disease
Primary: All-Cause Mortality — 3; 4 Participants — p=0.354
N/A N=21 Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Incidence Rate of All ADRs in Nintedanib Treated Patients — 11.0 patients with ADR events/100 pt-years
Phase 3 N=422 Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Metastatic Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 11.3; 12.0 Months — p=0.4342
Phase 3 N=476 Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
Acute Myocardial Infarction
Primary: Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels — -84.9; -82.2 pg/mL
N/A N=57 Evaluating Visual Acuity and Initial Fit Performance of Two Soft Contact Lenses
Visual Acuity
Primary: Monocular Distance Visual Acuity (logMAR) — -0.00; -0.00 logMAR
Phase 1 N=62 A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
Primary: Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A — 125 mg BID
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 2 N=31 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Biliary Tract Cancer
Primary: Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months — 54.8 percentage of participants
N/A N=100 Investigation of Patient Benefits With a New Supporting Ostomy Product in Patients With a Newly Stoma Formation
Stoma Ileostomy · Stoma Colostomy
Primary: Number of Times With Stoma Effluent Leakage Outside the Baseplate (e.g. Onto Clothes or Bedsheets) Within the Last 2 Weeks — 1.57; 0.93 Number of leakages per two weeks…
Phase 1 N=24 Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder
Healthy Volunteer · Opioid-use Disorder
Primary: Part I and Part II: Number of Participants With Adverse Events — 5; 2; 3; 8 Participants
Phase 2 N=42 Safety of L1-79 in Adolescent and Adult Males With Autism
Autism
Primary: Adverse Events — 2; 1; 2; 6 participants
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
N/A N=209 Evaluation of an Intervention for Young Adults With Diabetes: Resilient, Empowered, Active Living-Telehealth (REAL-T)
Diabetes Mellitus, Type 1
Primary: Change From Baseline to 6-months in Glycemic Control, Using Glycated Hemoglobin (HbA1C) — -0.44; -0.31 percentage of glycosylated hemoglobin